The study investigated the effectiveness and safety of abatacept (Orencia) for patients with rheumatoid arthritis (RA). The analysis concluded that abatacept gave better results to patients with RA compared to other biologic drugs. 

The study evaluated the effectiveness of compression bandages applied with different pressures on the skin and subcutaneous tissue in patients with breast cancer-related lymphedema (BCRL). The study concluded that high-pressure compression bandage was more effective in reducing skin and subcutaneous tissue thickness and inflammation in patients with BCRL. 

The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the risk of recurrence in these patients.

The study evaluated the effectiveness of aquatic therapeutic exercise in breast cancer survivors for improving symptoms and quality of life. The study found that aquatic therapeutic exercise effectively improved fatigue, pain, and quality of life in these patients.

This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving the overall survival of these patients.

This study evaluated the effects of aquatic physical therapy on improvement in fatigue symptoms and quality of life (QoL) in patients with breast cancer (BC). The data showed that aquatic physical therapy reduced fatigue symptoms and improved the QoL in women with BC.

The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to WBI in patients with early BC after breast-conserving surgery (BCS).

This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these patients with manageable side effects.

This study investigated the safety and effectiveness of ABX464 (Obefazimod) in patients with active rheumatoid arthritis (RA) with inadequate responses to methotrexate (Trexall) or anti-tumor necrosis factor alpha (anti-TNFα) treatment. The authors concluded that ABX464 was safe and well-tolerated with promising effectiveness in these patients at a daily dose of 50 mg.

This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak responders, additional immunization booster seems to be required, along with proactive planning in the vaccination schedule, with vaccine administration spaced out over time with respect to chemotherapy.